8-K: Tenaya Therapeutics Faces Nasdaq Delisting Warning

Tenaya Therapeutics received a Nasdaq notice for failing to meet the minimum bid price requirement, while also expanding its equity incentive plan to attract new talent.

Summary

• Received a letter from Nasdaq on January 28, 2026, indicating non-compliance with the minimum bid price rule of $1.00 per share for the 30 consecutive business days between December 12, 2025, and January 27, 2026.
• Granted a 180-calendar-day compliance period until July 27, 2026, to regain compliance with the minimum bid price requirement.
• The Board of Directors approved an amendment and restatement to the 2024 Inducement Equity Incentive Plan, increasing the number of shares reserved for issuance by an additional 2,161,000, bringing the aggregate total to 3,361,000 shares of common stock.
• The increase in shares for the Inducement Plan was adopted without stockholder approval, as permitted by applicable Nasdaq Listing Rules for inducement awards.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative development due to the Nasdaq delisting warning, which introduces uncertainty and risk, partially offset by the proactive measure to enhance talent retention through the expanded equity incentive plan.

Positives

• Expanded the 2024 Inducement Equity Incentive Plan by 2,161,000 shares, totaling 3,361,000 shares, to attract and retain key personnel, which is crucial for a development-stage biotechnology company.
• The Nasdaq notice has no immediate impact on the listing of the company's common stock, which will continue to be listed and traded on Nasdaq.
• The company has a 180-day compliance period, until July 27, 2026, to regain the minimum bid price requirement, providing time to address the deficiency.

Negatives

• Failed to meet Nasdaq's minimum bid price requirement of $1.00 per share for 30 consecutive business days, indicating a sustained period of low stock valuation.
• The company faces the risk of delisting from the Nasdaq Global Select Market if it does not regain compliance by the end of the initial compliance period or a potential second compliance period.
• The increase in shares reserved for the equity incentive plan, while beneficial for talent acquisition, could lead to dilution for existing shareholders.

Risks

• Delisting from Nasdaq: Failure to maintain a closing bid price of at least $1.00 for a minimum of ten consecutive business days during the compliance period (until July 27, 2026) could result in delisting.
• Inability to qualify for a Second Compliance Period: There is no assurance that the company will be eligible for an additional 180-day period or that Nasdaq would grant its request for continued listing subsequent to any delisting notification.
• Shareholder Dilution: The increase of 2,161,000 shares (to an aggregate of 3,361,000) under the Inducement Equity Incentive Plan could dilute the ownership percentage of existing shareholders.
• Impact on Investor Confidence: The delisting notice may negatively affect investor confidence, potentially impacting the company's stock price and its ability to raise capital in the future.

Future Outlook

The company intends to actively monitor the closing bid price of its common stock during the compliance period and may evaluate available options to resolve the deficiency and regain compliance. There is no assurance that the company will be able to regain or maintain compliance with Nasdaq listing standards.

Management Comments

• "The Company intends to actively monitor the closing bid price of its shares of common stock during the Compliance Period and may, if appropriate, evaluate available options to resolve the deficiency and regain compliance with the minimum bid price requirement."
• "While the Company is exercising diligent efforts to maintain the listing of its common stock on the Nasdaq Global Select Market, there can be no assurance that the Company will be able to regain or maintain compliance with the minimum bid price requirement or any other Nasdaq listing standard."

Industry Context

StockSavvy.ai notes that minimum bid price deficiencies are a common challenge for smaller biotechnology companies, particularly those in the clinical development stage like Tenaya Therapeutics, as their stock performance often correlates with pipeline progress and funding rather than immediate revenue. The expansion of the inducement equity plan, while potentially dilutive, is a standard practice in the biotech sector to attract and retain specialized scientific and executive talent crucial for drug development, especially when facing market pressures.

Corporate Governance

Stakeholder Impact

• Shareholders: Face potential dilution from the expanded equity incentive plan and the risk of delisting from Nasdaq, which could impact stock liquidity and valuation.
• Employees (New Hires): Benefit from enhanced equity-based incentives designed to attract and retain talent, offering a material inducement for employment.
• Nasdaq: The company's compliance status is under review, requiring adherence to listing rules to maintain its position on the exchange.

Next Steps

• Regain compliance with Nasdaq's minimum bid price requirement by maintaining a closing bid price of at least $1.00 for a minimum of ten consecutive business days by July 27, 2026.
• Evaluate available options to resolve the bid price deficiency, which may include a reverse stock split if eligible for a second compliance period.
• Continue to grant equity-based awards under the amended Inducement Plan to attract and retain employees.

Key Dates

Recommendation

The Nasdaq delisting notice introduces significant uncertainty and downside risk, warranting caution. However, the company has a compliance period to address the issue, and the expansion of the equity incentive plan indicates a continued focus on attracting talent, which is crucial for a development-stage biotech. Investors should hold to monitor the company's progress in regaining Nasdaq compliance and its strategic execution.

Keywords

Tenaya Therapeutics, TNYA, Nasdaq, Delisting, Minimum Bid Price, Equity Incentive Plan, Stock Options, Restricted Stock Units, Corporate Governance, Biotechnology, Gene Therapy, Cardiac Disease